Insight Molecular Diagnostics (IMDX) 25th Annual Needham Virtual Healthcare Conference summary

Strategic focus and product differentiation

• Shifted from oncology to transplant diagnostics, focusing on the GraftAssure test for higher margins and mature clinical utility.

• GraftAssure uses droplet digital PCR for precise, quantitative detection of donor DNA, differing from NGS-based competitors.

• Dual readout (relative and absolute quantification) offers improved long-term monitoring and clinical decision-making.

• Combination score of absolute and relative values enhances positive predictive value and biopsy yield.

Clinical development and adoption

• Ongoing studies include FDA submission, heart indication ramp-up, and the GALACTIC registry for long-term value assessment.

• Demonstrated strong performance in heart, lung, liver, and kidney transplants; registry aims to enroll up to 5,000 patients over 3–5 years.

• Early data supports detection of T-cell-mediated rejection, with further research ongoing.

• Routine screening protocol centers on four tests in the first year and two annually thereafter for kidney patients.

Market strategy and expansion

• Targeting 50 U.S. centers for registry participation, with 37 already engaged, including 11 international sites.

• FDA clearance expected to accelerate adoption; European IVDR submission planned for late Q2/Q3, with potential clearance in Q1 next year.

• U.S. market is highly concentrated, with top 100 centers performing 80% of transplants and most equipped for in-house testing.

• Reference labs expected to serve smaller centers lacking molecular lab capabilities.